Canaccord Genuity reiterated their hold rating on shares of Entellus Medical, Inc. (NASDAQ:ENTL) in a research note issued to investors on Tuesday, October 17th. Canaccord Genuity currently has a $17.00 price target on the medical technology company’s stock.
A number of other analysts have also issued reports on the company. Zacks Investment Research upgraded Entellus Medical from a sell rating to a buy rating and set a $23.00 price target for the company in a report on Monday, October 9th. Piper Jaffray Companies reiterated a buy rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, BidaskClub upgraded Entellus Medical from a hold rating to a buy rating in a report on Saturday, August 19th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $21.86.
Entellus Medical (NASDAQ:ENTL) traded down 0.086% on Tuesday, hitting $17.515. The stock had a trading volume of 21,918 shares. Entellus Medical has a 1-year low of $12.31 and a 1-year high of $20.46. The stock’s 50-day moving average is $18.33 and its 200 day moving average is $18.33. The firm’s market capitalization is $444.37 million.
Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). The business had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.27) EPS. On average, equities research analysts predict that Entellus Medical will post ($1.61) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/entellus-medical-inc-entl-receives-hold-rating-from-canaccord-genuity.html.
In other Entellus Medical news, VP Timothy B. Petrick sold 2,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Kevin L. Mensink sold 2,500 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $19.00, for a total value of $47,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,150 shares of company stock valued at $1,740,652. 7.70% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in Entellus Medical during the first quarter worth $290,000. Nicholas Company Inc. lifted its holdings in Entellus Medical by 1,052.3% during the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after buying an additional 226,190 shares during the period. Swiss National Bank lifted its holdings in Entellus Medical by 98.9% during the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after buying an additional 8,800 shares during the period. William Blair Investment Management LLC lifted its holdings in Entellus Medical by 10.5% during the second quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock worth $7,140,000 after buying an additional 40,853 shares during the period. Finally, Archon Capital Management LLC lifted its holdings in Entellus Medical by 34.3% during the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock worth $7,929,000 after buying an additional 122,171 shares during the period. Institutional investors own 70.27% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.